{"type":"trials","record":{"id":5289,"source_id":"clinicaltrials-gov","external_id":"NCT07114536","title":"Evaluation of the Efficacy of Calcium a -Ketoglutarate(AKG-Ca) in Improving Human Aging","brief_summary":"This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effects of calcium alpha-ketoglutarate (CaAKG) supplementation on biological aging and age-related health indicators in middle-aged and older adults. Alpha-ketoglutarate (AKG), a key intermediate in the Krebs cycle, has been investigated for its potential role in modulating aging-related metabolic and cellular pathways. Due to the poor oral bioavailability of free AKG, its stabilized form-calcium alpha-ketoglutarate (CaAKG)-is used to enhance absorption and additionally provides calcium supplementation benefits. At the population level, there is currently a lack of systematic assessment studies on the effects of CaAKG on human ageing-related indicators. The study will recruit generally healthy adults aged 45 to 75 years. Participants will be randomly assigned to receive either CaAKG or a placebo daily for 12 weeks. The primary objective is to assess changes in biological aging, as measured by PhenoAge. Secondary outcomes include changes in physical performance, inflammatory markers, glucose and lipid metabolism, ageing-related gene expression, and self-reported quality of life. This trial is designed to provide evidence on the efficacy and safety of CaAKG as a potential dietary intervention to support healthy aging. All participants will undergo pre- and post-intervention assessments. The study has been reviewed and approved by Medical Ethics Committee of Zhejiang Chinese Medical University, and informed consent will be obtained from all participants prior to enrollment.","overall_status":"Completed","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Shenzhen Hygieia Biotech Co., Ltd","enrollment":34,"countries":["China"],"start_date":"2025-08-20","completion_date":"2025-11-30","last_update_date":"2026-09-16","source_url":"https://clinicaltrials.gov/study/NCT07114536","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-16T12:17:04.12803+00:00","last_seen_at":"2026-09-25T06:15:13.984+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"40 Years to 75 Years","comparator":"Control group: starch","organization":"Shenzhen Hygieia Biotech Co., Ltd","interventions":["Calcium-a-ketoglutarate","Placebo(starch)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in PhenoAge from Baseline to Week 12 — Baseline and Week 12","Change in Calcium Content of Bone — Baseline and Week 12","Change in β-Galactosidase Activity — Baseline and Week 12","Change in Age-related Gene Expression — Baseline and Week 12","Change in Grip strength — Baseline,12-week study","Change in body Weight — Baseline and Week 12","Change in body mass index(BMl) — Baseline and Week 12","Change in body fat mass — Baseline and Week 12","Change in alkaline phosphatase (ALP) — Baseline and Week 12","Change in body fat percentage — Baseline and Week 12","Change in fat-free mass — Baseline and Week 12","Change in muscle mass — Baseline and Week 12","Change in body water — Baseline and Week 12","Change in blood creatinine (CREA) — Baseline and 12-week study.","Change in protein — Baseline and Week 12","Change in inorganic salts — Baseline and Week 12","Change in TotalT lymphocytes (CD3+) — Baseline and Week 12","Change in helper T cells(cD4+) — Baseline and Week 12","Change in cytotoxicT cells(CD8+) — Baseline and Week 12","Change in Glycated haemoglobin (HbAlc) — Baseline and Week 12"],"design_description":"RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE","source_has_results":false},"controlled_terms":["Aging","Calcium-a-ketoglutarate","Placebo(starch)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: akg.","quality_checked_at":"2026-09-25T06:15:15.562724+00:00","duplicate_cluster_key":"id:nct07114536","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-08-20 to 2025-11-30","comparator":"Control group: starch","confidence":"structured-source","population":"ALL · 40 Years to 75 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:13.985Z","intervention":["Calcium-a-ketoglutarate","Placebo(starch)"],"participants":34,"study_design":"RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in PhenoAge from Baseline to Week 12 — Baseline and Week 12","Change in Calcium Content of Bone — Baseline and Week 12","Change in β-Galactosidase Activity — Baseline and Week 12","Change in Age-related Gene Expression — Baseline and Week 12","Change in Grip strength — Baseline,12-week study","Change in body Weight — Baseline and Week 12","Change in body mass index(BMl) — Baseline and Week 12","Change in body fat mass — Baseline and Week 12","Change in alkaline phosphatase (ALP) — Baseline and Week 12","Change in body fat percentage — Baseline and Week 12","Change in fat-free mass — Baseline and Week 12","Change in muscle mass — Baseline and Week 12","Change in body water — Baseline and Week 12","Change in blood creatinine (CREA) — Baseline and 12-week study.","Change in protein — Baseline and Week 12","Change in inorganic salts — Baseline and Week 12","Change in TotalT lymphocytes (CD3+) — Baseline and Week 12","Change in helper T cells(cD4+) — Baseline and Week 12","Change in cytotoxicT cells(CD8+) — Baseline and Week 12","Change in Glycated haemoglobin (HbAlc) — Baseline and Week 12"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"alpha-ketoglutarate","is_published":true,"match_reasons":["Title contains controlled term: akg.","Abstract contains controlled term: alpha-ketoglutarate, akg.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Alpha-ketoglutarate","slug":"alpha-ketoglutarate"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/5289","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}